Benylin Chesty Coughs

Quick links

Choose a section

Quick links to important sections

Advertisements

Benylin Chesty Coughs

Advertisements
Advertisements

Method of action: Expectorant

Treatment option: Cough

Advertisements

Overview of Benylin Chesty Coughs

Quick Facts

Property Description
Active ingredient Guaifenesin, Levomenthol
Form Oral Solution or Syrup
Pharmacological class Expectorant and Decongestant
Common use Relief for productive or chesty coughs
Origin Synthetic (Guaifenesin) and Naturally derived (Levomenthol)

Defining Benylin Chesty Coughs: Classification and Core Ingredients

Benylin Chesty Coughs is a proprietary non-drowsy combination medicine, widely recognized across the UK and other markets, supplied as an oral solution or syrup specifically for oral use. It is categorized as an expectorant and decongestant preparation, a classification that establishes its primary mechanism of action against respiratory congestion. The core active components are the well-established expectorant, Guaifenesin, and the ancillary decongestant agent, Levomenthol.

The therapeutic role of Guaifenesin as an expectorant involves its function in reducing the viscosity of respiratory secretions, which assists the body in clearing the airways. This therapeutic effect is central to the medicine’s purpose, helping to make the cough reflex more productive at removing stubborn phlegm.

What is the Form and Differentiating Features of the Medicine?

The medicine is supplied as a liquid syrup or clear oral solution, which is the intended dosage form for liquid preparations requiring oral administration. The Guaifenesin component is a synthetic compound, whereas Levomenthol is a stereoisomer of menthol that is naturally derived. A key differentiating feature of this specific formulation is its non-drowsy designation, achieved by deliberately excluding sedative components common in other multi-action cold remedies. This allows individuals to maintain normal daytime activity without impairment from sedation.

General Purpose: Relief for Productive and Chesty Coughs

The overarching purpose of Benylin Chesty Coughs is to provide targeted symptomatic relief for a productive cough, which is characterized by the accumulation of excess mucus in the chest. By simultaneously targeting bronchial congestion and the thickness of the trapped secretions, the medicine works to facilitate airway clearance.

The inclusion of Levomenthol provides a soothing, local effect that helps ease the feeling of congestion due to its established anesthetic properties. Its primary benefit is therefore rooted in making the cough effective, enabling the patient to clear the respiratory tract more efficiently, thus addressing the mechanical discomfort associated with the heavy accumulation of phlegm.

Advertisements

What side effects are possible with Benylin Chesty Coughs?

Possible Side Effects and Safety Information

The official safety profile for medicines containing Guaifenesin and Levomenthol (Menthol) is organized by regulatory bodies to communicate documented adverse reactions and contextual safety constraints. Adverse reactions reported during post-marketing use are frequently classified as Not Known, meaning their exact frequency cannot be reliably estimated from available data.


Documented Adverse Reactions by System Organ Class

Adverse effects listed in regulatory documents are generally categorized into specific physiological domains, reflecting the systems most commonly affected by the active ingredients.

System Organ Class Examples of Documented Reactions
Gastrointestinal Disorders Nausea, Vomiting, Abdominal Discomfort
Immune System Disorders Hypersensitivity reactions, Anaphylactic reactions, Angioedema
Skin and Subcutaneous Tissue Disorders Rash, Urticaria

Serious Reactions and Contextual Safety Constraints

The regulatory safety summary lists certain Hypersensitivity Reactions such as Anaphylactic Reactions and Angioedema as rare but potentially serious adverse events reported in association with the active ingredients. These reactions involve the immune system and can affect the skin and respiratory function.

Official labeling includes specific safety considerations for patient populations and pre-existing conditions. Caution is exercised for use in individuals with severe hepatic or severe renal impairment. Additionally, the medicine is not intended for use in individuals with a persistent or chronic cough, such as one associated with asthma or smoking, or a cough involving excessive mucus, unless specifically advised by a healthcare professional. Guaifenesin may also interfere with laboratory tests for urinary 5-HIAA and VMA.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help: Official Regulatory Information

The official overdose documentation for the active ingredients outlines specific clinical manifestations and mandated emergency actions. Acute over-exposure may primarily affect the gastrointestinal system, presenting with nausea, vomiting, abdominal discomfort, and diarrhea. Signs of central nervous system involvement, such as drowsiness or, in extreme cases of toxicity, convulsions or unconsciousness, are also documented. While the effects of Guaifenesin alone are generally classified as temporary and reversible, high-level over-exposure may lead to severe or life-threatening complications.

Immediate Actions Required

  • Contact a Poison Control Center or seek immediate medical help right away in all cases of suspected overdose.
  • Call emergency services immediately if the person has collapsed, had a seizure, has trouble breathing, or cannot be awakened.

Management and Monitoring

The management protocol is classified as symptomatic and supportive treatment, as no specific antidote is known for the active components. Procedures may include monitoring of vital signs and electrolytes, administration of activated charcoal to reduce absorption, and fluid replacement to manage severe vomiting. The official profile emphasizes immediate medical intervention for any suspected case, due to the range of effects from gastrointestinal distress to severe central nervous system signs.

Advertisements

Therapeutic Uses of Benylin Chesty Coughs

What Benylin Chesty Coughs Treats: Main Uses and Benefits

The core therapeutic utility of the main active ingredient is directed toward providing symptomatic relief for congested chests and coughs associated with the common cold.

This medicine is commonly used to help with symptomatic relief for acute respiratory illnesses that involve a chesty or productive cough and bronchial congestion. It is applied in situations where symptoms involve thick, sticky mucus in the chest, and the body requires additional support for clearance. The core benefit may assist with managing the viscosity of these secretions, which is relevant for promoting a more effective cough, and contributes to improved comfort during periods of heightened symptoms.

It is used for managing the symptom cluster of chest heaviness and bronchial congestion caused by the accumulation of respiratory secretions. This supportive therapeutic benefit is relevant for easing the uncomfortable sensation of pressure or tightness in the chest. Furthermore, as a non-sedating formula, it is considered relevant for individuals who require supportive symptomatic assistance without the potential for unwanted sedation, supporting the maintenance of functional stability during the day.


“This medicine is relevant for easing the uncomfortable sensation of chest heaviness and pressure.”


Quick Facts: Symptomatic Support for Productive Cough

  • Symptom Domains: Viscous secretions, chest heaviness, bronchial congestion, and acute cough discomfort.
  • Patient Benefit: Assists with mucus clearance and contributes to easing the overall symptom load during daytime hours.

Regulatory References

  1. TGA OTC Medicine Monograph: Guaifenesin
Advertisements

Eligibility and Restrictions for Use

Official Population Eligibility for Benylin Chesty Coughs

Regulatory documents establish specific rules defining who is eligible to use this medicine and who is strictly excluded.

Category Eligibility Status
Approved Age Group Adults and adolescents aged 12 years and over.
Absolute Contraindication Children under 12 years.
Physiological Status Not recommended for women who are pregnant or breastfeeding.
Condition-Specific Use is contraindicated if there is known hypersensitivity to Guaifenesin, Levomenthol, or any excipients.

Absolute prohibition applies to individuals with specific conditions, including rare hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase-isomaltase insufficiency, due to the sugar content in the oral solution. Use also requires caution in patients diagnosed with severe renal impairment or severe hepatic impairment, as officially stated in the product information.

Furthermore, the medicine should not be used for a persistent or chronic cough, such as one associated with asthma or emphysema, or if the cough is accompanied by excessive secretions, unless explicitly directed otherwise.

Advertisements

What should I know about interactions with other medicines?

The official regulatory profile for Guaifenesin and Levomenthol formulations indicates a low overall risk for drug-to-drug interactions, with no documented pharmacokinetic interactions involving the CYP enzyme system.

Drug and Substance Interactions

Co-administration with cough suppressants (antitussives), such as Dextromethorphan or codeine-containing medicines, is generally not recommended by regulatory agencies. This restriction is based on a pharmacological conflict, as Guaifenesin works to promote mucus clearance while suppressants inhibit the cough reflex.

Procedural Interference: Guaifenesin can cause interference with specific laboratory tests. A metabolite may cause a color interference during the determination of urinary 5-hydroxyindoleacetic acid (5-HIAA) and vanillylmandelic acid (VMA) if urine is collected within 24 hours of administration.

  • The absorption of Guaifenesin is unaffected by food and may be administered independently of meals.
  • Certain liquid formulations contain ethanol (alcohol), which must be considered for patients concurrently taking other medications or those advised to avoid alcohol consumption.

Population and Excipient Constraints

Caution is formally advised for use in patients with severe hepatic (liver) impairment and severe renal (kidney) impairment, due to potential effects on drug clearance. Furthermore, patients with diabetes mellitus or those on a controlled sodium diet must account for the sugar (sucrose/glucose) and sodium content found in some liquid formulations, as outlined in official prescribing information.

Advertisements

Mechanism of Action

Modulation of Mucoactive Secretory Pathways

This mechanism, driven by the expectorant component, acts by engaging a gastro-pulmonary reflex that influences bronchial gland activity. It initiates a signaling sequence that leads to an increased production of watery secretions in the airways, resulting in an effective reduction in the viscosity (thickness) of the mucus. This modification of early molecular steps supports an increase in the efficiency of mucociliary clearance.


Dampening Central Cough Reflex Signaling

Where an antitussive component is present, it supports the regulation of processes driven by distinct signaling patterns in the central nervous system. This component modulates activity in the medullary cough center of the brainstem, engaging mechanisms that regulate an overactive or dysregulated cough reflex. This targeted pathway adjustment leads to an elevation of the cough threshold, contributing to the regulation of overactive signaling within the central reflex arc and influencing signaling that governs the frequency of reflex activation.

Advertisements

Dosage and Administration Information

Administration Guidelines for Benylin Chesty Coughs

This section outlines the standardized usage protocol for Benylin Chesty Coughs (Guaifenesin 100 mg/5 ml and Levomenthol 1.1 mg/5 ml oral solution).


The medicine is supplied as a syrup and is designated exclusively for the oral route of administration. The proper use of this liquid preparation requires an accurate 10 ml dose volume, typically measured using a suitable device. The formulation does not require dilution or special preparation prior to consumption.

Dosage and Frequency Regimens

Population Single Dose Volume Maximum Frequency Maximum Daily Dose
Adults and Children ge 12 years 10 ml (Two 5 ml spoonfuls) Every 4 to 6 hours 40 ml (4 doses/24 hours)
The Elderly As for adults As for adults As for adults
Children under 12 years Not Recommended/Contraindicated N/A N/A

All patients must adhere to the constraint of not exceeding four doses within any 24-hour period.

Population-Specific Use and Duration

The use of this specific product is not recommended for children under the age of 12 years. For the elderly, the dosage is identical to the adult regimen. Caution should be exercised when administering this product in the presence of severe renal or hepatic impairment. The medicine is intended for short-term symptomatic use, and a healthcare professional should be consulted if symptoms persist.

Advertisements

Recent Clinical Evidence

Recent Clinical Evidence

The formulation of Benylin Chesty Coughs (Original) contains two primary active ingredients, Diphenhydramine (an antihistamine with antitussive properties) and L-Menthol (for local soothing effects). The clinical evidence for these compounds relates primarily to their known properties as studied in respiratory research.


Studies on Diphenhydramine

Clinical data indicates that Diphenhydramine possesses antitussive (cough-suppressing) properties, distinct from its primary antihistaminic action. Studies suggest this antitussive effect is likely due to an action on the brainstem.

Pharmacokinetic research has evaluated the compound’s profile, noting that it is well-absorbed following oral administration and is widely distributed throughout the body. The duration of its activity in the body has been assessed to be between four and eight hours.

Tolerability and Safety Profile

Research has explored the tolerability profile of the drug's components:

  • Observed Side Effects: The use of Diphenhydramine has been associated with side effects, including drowsiness, dizziness, and gastrointestinal disturbances. Research has also documented anticholinergic effects such as dry mouth, difficulty in urination, or blurred vision.
  • Special Populations: Studies have examined the effect of impaired kidney function, suggesting that for moderate to severe renal failure, the dosing interval may warrant extension, dependent on the individual's glomerular filtration rate (GFR). The potential for the compound to cross the placenta and be excreted into breast milk has also been a subject of research.

Role of L-Menthol

L-Menthol is included primarily for its mild local anaesthetic and decongestant properties. Research suggests that at the low concentration present in the product, adverse reactions are not anticipated. Its role is often studied in the context of providing a local, soothing effect in the throat and airways.

Key Studies & References

  1. Diphenhydramine - Drugs and Lactation Database (LactMed®) - NCBI Bookshelf (Excretion into breast milk)
  2. Menthol - Wikipedia (Local anesthetic and cooling mechanism)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Benylin Chesty Coughs (FAQ)

Q: Will this drug affect my sleep or make me tired?

Official product information indicates that somnolence (sleepiness) and dizziness are among the most common adverse reactions reported with this medication. Official product information suggests exercising caution and monitoring for changes in alertness while taking this medication.

Q: Can I drink alcohol while taking this medication?

Official product warnings advise avoiding alcoholic beverages while taking this medication. Combining alcohol with the drug can increase the risk of central nervous system side effects such as drowsiness and dizziness.

Q: Does this drug cause weight gain?

Official regulatory documents list weight gain and an increased appetite among the common adverse reactions reported with this treatment. Patients who have diabetes and experience weight gain should consult their healthcare provider to determine if adjustments to their current hypoglycaemic medications are necessary.

Q: Is it safe to stop taking this drug suddenly?

Official product information suggests that if discontinuation is necessary, it should generally be done gradually over a minimum of one week. This approach is recommended to help reduce the potential risk of withdrawal symptoms, such as increased seizure frequency.

Q: Can I drive or operate machinery while on this treatment?

Due to the potential for side effects like dizziness and somnolence (sleepiness), the medication may impair a person's ability to drive or operate complex machinery. Patients are advised to exercise caution and should generally not drive or operate complex machinery until they know how this medication affects their ability to perform these activities.

Q: Can children under 18 take this medication?

The safety and effectiveness of this medication have not been established for children below the age of 12 years or for adolescents aged 12 to 17 years for the currently approved uses. Official documentation confirms that no posology (dosing recommendation) has been established for these younger populations.

Q: What is the most serious side effect I should look out for?

According to official safety information, some of the most serious effects reported include severe allergic reactions like angioedema (swelling of the face, throat, and tongue) and other serious hypersensitivity reactions. Official warnings also note that suicidal thoughts and behavior have been reported in a small number of patients taking this class of medication.

Q: Can I take this for pain that is not nerve-related?

The approved therapeutic indications listed in regulatory documents are specific: treatment of peripheral and central neuropathic pain in adults, Generalised Anxiety Disorder (GAD), and as an add-on therapy for partial seizures. The documents do not list indications for non-nerve related or general pain conditions.

Q: Does it affect my vision?

Blurred vision and diplopia (seeing double) are listed as common adverse effects in regulatory product information. In addition, there have been post-marketing reports of changes in visual clarity, including temporary or permanent loss of vision.

Q: Will this medicine interfere with my birth control pills?

According to official consumer information, this medication does not interfere with the effectiveness of oral contraceptives (birth control pills).

Advertisements

How should Benylin Chesty Coughs be stored and disposed of?

Storage and Disposal of Benylin Chesty Coughs

Official regulatory guidelines define specific conditions to maintain the stability of Benylin Chesty Coughs preparations.

Storage Requirements

Condition Requirements as Labeled
Temperature Must not store above 25 C (Original/Children's) or above 30 C (Non-Drowsy). The product must not be frozen.
Container/Handling Must be stored in the original package and kept tightly closed to protect from moisture.
Child Safety The medicine must be kept out of the sight and reach of children at all times.

Stability and Disposal

Specific products, such as Benylin Chesty Coughs Original and Children's, must be discarded 4 months after opening the bottle, even if product remains.

Expired or unused Benylin Chesty Coughs must not be disposed of in household waste or flushed into wastewater. To comply with environmental protection rules, the user is instructed to consult a pharmacist for guidance on proper disposal according to local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Benylin Chesty Coughs found in:

A-Z Index: